CAAS Introduces Rear-Wheel Active Steering Technology to Upper Mass-Market EVs in China
WUHAN, China, Oct. 21, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced that with the rapid growth of automotive...
2025 Chery International User Summit: Shaping the Industry's Future Through Co-Creation and Innovation
WUHU, China, Oct. 21, 2025 /PRNewswire/ -- On October 21, 2025, the 2025 Chery International User summit — a global gathering transcending geography and culture — was grandly held in Wuhu, China. With the theme "Co-Create, Co-Define," the event...
PORTMAG Secures Patents in 25 Countries with Magnetic Connector Technology -- Leading the Next Generation of Charging Solutions
SEOUL, South Korea, Oct. 21, 2025 /PRNewswire/ -- Korean tech company PORTMAG Co., Ltd. is gaining global recognition for its proprietary magnetic connector technology. Building on its core innovation, the company has completed patent registrations...
Casio to Release Ring-Sized G-SHOCK
Shock-Resistant Structure and 200-Meter Water Resistance Packed in Smallest Size in Brand's History TOKYO, Oct. 21, 2025 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the release of the DWN-5600, a new G-SHOCK watch that incorporates...
Ulanzi: A Quiet Force Behind the Global Creator Movement
SHENZHEN, China, Oct. 20, 2025 /PRNewswire/ -- In the age of short videos and digital storytelling, creativity has become a universal language. From vloggers filming on the move to professionals building personal studios, the demand for smarter and...
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). OS was significantly...
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally...
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate...
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...